



Lund May 27, 2014

EXINI and FUJIFILM RI Pharma co-sponsors seminar on BSI and Imaging Biomarkers at the Sweden Life Science Summit, May 23-24, at the Swedish Embassy in Tokyo

Last Friday, the Swedish Ambassador to Japan opened the Sweden Life Science Summit 2014, held in the Alfred Nobel Auditorium, hosted by the Swedish Embassy and by Business Sweden in Tokyo. EXINI Diagnostics AB and FUJIFILM RI Pharma, both early supporters of the summit, co-sponsored the seminar on the imaging biomarker BSI (*Bone Scan Index*), attracting senior medical experts, physicians and executives from pharmaceutical industry, hospitals and universities.

The Sweden Life Science Summit 2014 in Tokyo brought together participants from pharmaceutical industry and academia with officials from both Japan and Sweden. The seminar on BSI demonstrated widespread benefits to be gained from using the imaging biomarker Bone Scan Index in clinical workflow or in pharmaceutical development.

“The EXINI – FUJIFILM RI Pharma partnership stands out as the good example, clearly demonstrating win-win benefits through collaboration between large international corporations and innovative science –based companies”, states Cecilia Öberg Leiram, Trade Commissioner to Japan, Business Sweden.

“The imaging biomarker BSI makes it possible to stratify patients in order to optimize treatment strategies, evaluate treatment responses, and make prognosis of disease outcomes”, explains Dr. Kenichi Nakajima, Kanazawa University.

“EXINI bone^{BSI} is available world wide and I am convinced that the close relationship between us, FUJIFILM RI Pharma and the University of Kanazawa, will continue to bring about new innovative products for the global market”, comments Magnus Aurell CEO, EXINI Diagnostics AB.

More on Bone Scan Index (BSI):

BSI is an imaging biomarker providing fast, accurate and quantifiable information to be used for diagnose and stratification, monitoring of treatment response and increased accuracy in prognoses tending to patients suffering from skeletal metastases originating from prostate- or breast cancer.

BSI has also demonstrated its importance in the process of developing new drugs, thus proving itself equally important for clinical use as for pharmaceutical industry. EXINI bone^{BSI} serves as the only software capable to extract BSI-value for both these purposes.

www.bonescanindex.org
www.exini.com/software-bone-bsi/
www.business-sweden.se

For more information, please contact:

Magnus Aurell, CEO
Phone: +46 46-286 54 25
E-mail: magnus.aurell@exini.com

About EXINI Diagnostics AB (publ)

EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 600 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkommission AB acts as Certified Advise